Multipl skleroz (MS) hastal\u0131\u011f\u0131, merkezi sinir sistemindeki beyin ve omurilikteki sinir h\u00fccrelerini etkileyen kronik bir hastal\u0131kt\u0131r. MS hastal\u0131\u011f\u0131, s\u0131kl\u0131kla genetik fakt\u00f6rler, enfeksiyonlar ve \u00e7evresel fakt\u00f6rler gibi bir\u00e7ok fakt\u00f6r\u00fcn etkisi alt\u0131nda geli\u015febilir. Bu hastal\u0131kta, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi myelin denilen sinir h\u00fccrelerinin koruyucu k\u0131l\u0131f\u0131na sald\u0131rarak bunun zarar g\u00f6rmesine neden olur. MS, belirtileri ve etkileri bak\u0131m\u0131ndan \u00e7ok \u00e7e\u015fitli olabilir ve yayg\u0131n semptomlar aras\u0131nda g\u00fc\u00e7s\u00fczl\u00fck, dengesizlik, koordinasyon kayb\u0131 ve yorgunluk bulunur. MS i\u00e7in \u015fu anda tedavi edilemeyen bir hastal\u0131kt\u0131r, ancak baz\u0131 ila\u00e7 tedavileri MS semptomlar\u0131n\u0131 y\u00f6netmek i\u00e7in kullan\u0131l\u0131r.<\/p>\n\n\n\n
MS ile ya\u015fayan bir\u00e7ok ki\u015fi i\u00e7in, tedaviler semptomlar\u0131 y\u00f6netmek ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatmak i\u00e7in kullan\u0131lan baz\u0131 ila\u00e7lar\u0131 i\u00e7erir. Ge\u00e7ti\u011fimiz y\u0131llarda, MS i\u00e7in geli\u015ftirilen yeni tedaviler ortaya \u00e7\u0131kt\u0131 ve bu hastal\u0131\u011fa yakalananlar\u0131n hayat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde de\u011fi\u015ftirebilecek ilerlemeler sa\u011flam\u0131\u015flt\u0131r.<\/p>\n\n\n\n
Ocrelizumab<\/strong> Daclizumab<\/strong> Alemtuzumab<\/strong> Siponimod<\/strong> Ozanimod<\/strong> Fingolimod<\/strong> Teriflunomide<\/strong> Natalizumab<\/strong> Mitoksantron<\/strong> Interferonlar<\/strong> Daha spesifik olarak, Avonex, Betaseron, Copaxone, Extavia ve Rebif gibi interferonlar MS tedavisinde en yayg\u0131n kullan\u0131lan ila\u00e7lard\u0131r.<\/p>\n\n\n\n Glatiramer Asetat Dimetil Fumarat Natalizumab<\/strong> Multipl skleroz (MS) hastal\u0131\u011f\u0131, merkezi sinir sistemindeki beyin ve omurilikteki sinir h\u00fccrelerini etkileyen kronik bir hastal\u0131kt\u0131r. MS hastal\u0131\u011f\u0131, s\u0131kl\u0131kla genetik<\/p>\n","protected":false},"author":1,"featured_media":272,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_container_layout":"default_layout","colormag_page_sidebar_layout":"default_layout","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"_joinchat":[],"footnotes":""},"categories":[24],"tags":[19,21,23,22,20,6],"class_list":["post-270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hastaliklar","tag-doktor","tag-ms","tag-ms-hastaligi","tag-ms-tedavi","tag-multiple-skleroz","tag-noroloji"],"yoast_head":"\n
Ocrelizumab, MS hastalar\u0131n\u0131n hastal\u0131k ilerlemesini yava\u015flatarak semptomlar\u0131n\u0131 iyile\u015ftirmeye yard\u0131mc\u0131 olabilir. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerini kontrol etmek i\u00e7in tasarlanm\u0131\u015f olan bu ila\u00e7, myelin denilen sinir h\u00fccrelerini koruyan proteinleri artt\u0131r\u0131r. MS tedavi se\u00e7enekleri aras\u0131nda FDA taraf\u0131ndan onaylanan ilk ila\u00e7t\u0131r.<\/p>\n\n\n\n
Daclizumab, MS hastal\u0131\u011f\u0131 i\u00e7in tasarlanm\u0131\u015f bir ba\u015fka ila\u00e7t\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerine etki ederek n\u00f6rolojik h\u00fccrelere sald\u0131ran h\u00fccrelerin say\u0131s\u0131n\u0131 azalt\u0131r. MS semptomlar\u0131n\u0131 y\u00f6netmek i\u00e7in kullan\u0131lan ila\u00e7lardan biridir.<\/p>\n\n\n\n
Alemtuzumab, MS hastal\u0131\u011f\u0131 olan ki\u015filer i\u00e7in onaylanm\u0131\u015f bir ba\u015fka ila\u00e7t\u0131r. Bu ila\u00e7, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin say\u0131s\u0131n\u0131 azaltarak v\u00fccuttaki h\u00fccrelerin etkilenmesini \u00f6nler. Hastalar\u0131n MS semptomlar\u0131n\u0131 y\u00f6netmek i\u00e7in kullanabilecekleri ba\u015fka bir tedavi se\u00e7ene\u011fidir. Alemtuzumab’\u0131n kullan\u0131m\u0131n\u0131n baz\u0131 riskleri olabilir, bu nedenle hastalar\u0131n tedavi se\u00e7ene\u011finin uygunlu\u011funu doktorlar\u0131 ile tart\u0131\u015fmas\u0131 \u00f6nerilir.<\/p>\n\n\n\n
Siponimod, 2019 y\u0131l\u0131nda FDA taraf\u0131ndan onaylanan bir ila\u00e7t\u0131r ve MS hastalar\u0131 i\u00e7in tedavi se\u00e7eneklerinden biridir. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin say\u0131s\u0131n\u0131 azaltarak n\u00f6rolojik h\u00fccrelerin ayr\u0131lmalar\u0131n\u0131 azaltabilir. MS semptomlar\u0131n\u0131n y\u00f6netilmesine yard\u0131mc\u0131 olabilir.<\/p>\n\n\n\n
Ozanimod, MS hastal\u0131\u011f\u0131 i\u00e7in tasarlanm\u0131\u015f ba\u015fka bir ila\u00e7t\u0131r. Bu ila\u00e7, MS hastal\u0131\u011f\u0131 taraf\u0131ndan neden olabilecek hasar\u0131n azalt\u0131lmas\u0131na yard\u0131mc\u0131 olabilecek n\u00f6rolojik h\u00fccrelerin korunmas\u0131na yard\u0131mc\u0131 olur. Ayn\u0131 zamanda interferon tedavisinin yerini alabilir ve MS hastalar\u0131nda yayg\u0131n olan seyahat hastal\u0131\u011f\u0131, ba\u015f d\u00f6nmesi ve bulant\u0131 gibi yan etkilere neden olabilir.
<\/p>\n\n\n\n
Fingolimod, MS hastal\u0131\u011f\u0131n\u0131n tedavisinde kullan\u0131lan bir ba\u015fka ila\u00e7t\u0131r. Bu ila\u00e7, beyindeki ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin sinir h\u00fccrelerine sald\u0131rmas\u0131n\u0131 \u00f6nleyerek etki g\u00f6sterir. Semptomlar\u0131n\u0131n \u015fiddetini azaltabilir ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatabilir.<\/p>\n\n\n\n
Teriflunomide, MS hastalar\u0131 i\u00e7in kullan\u0131lan bir ba\u015fka ila\u00e7t\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin aktivitesini azaltarak n\u00f6rolojik h\u00fccrelere zarar verme riskini azalt\u0131r. MS semptomlar\u0131n\u0131 y\u00f6netmek i\u00e7in yayg\u0131n olarak kullan\u0131lan bir tedavi se\u00e7ene\u011fidir.<\/p>\n\n\n\n
Natalizumab, MS hastalar\u0131na yard\u0131mc\u0131 olmas\u0131 i\u00e7in kullan\u0131lan ba\u015fka bir ila\u00e7t\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin beyne giri\u015fini engelleyerek sinir h\u00fccrelerini koruyabilir. Hastalar\u0131n semptomlar\u0131n\u0131 kontrol alt\u0131na almak ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatmak i\u00e7in kullan\u0131labilir.<\/p>\n\n\n\n
Mitoksantron, MS’in ilerlemesini yava\u015flatmak ve semptomlar\u0131 hafifletmek i\u00e7in kullan\u0131lan bir kemoterapi ilac\u0131d\u0131r. Bu ila\u00e7, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin aktivitesini bask\u0131lar ve hastal\u0131\u011f\u0131n bir\u00e7ok semptomunu iyile\u015ftirebilir. Ancak, mitoksantronun baz\u0131 yan etkileri ve ciddi riskleri vard\u0131r, bu nedenle bir uzman taraf\u0131ndan dikkatlice takip edilmelidir.<\/p>\n\n\n\n
Interferonlar, MS hastal\u0131\u011f\u0131n\u0131n tedavisinde yayg\u0131n olarak kullan\u0131lan bir ila\u00e7 s\u0131n\u0131f\u0131d\u0131r. Bu ila\u00e7lar, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin aktivitesini azaltarak n\u00f6rolojik hasar\u0131 \u00f6nlemeye \u00e7al\u0131\u015f\u0131r. Relapsing-remitting MS (RRMS) semptomlar\u0131n\u0131n kontrol alt\u0131na al\u0131nmas\u0131na yard\u0131mc\u0131 olabilir.<\/p>\n\n\n\n
<\/strong>Glatiramer asetat, MS’in tedavisinde kullan\u0131lan ba\u015fka bir ila\u00e7t\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin myelin zarar\u0131 vermeye \u00e7al\u0131\u015fan h\u00fccrelere kar\u015f\u0131 tepkisini de\u011fi\u015ftirerek etki g\u00f6sterir. RRMS semptomlar\u0131n\u0131 hafifletebilir ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatabilir.<\/p>\n\n\n\n
<\/strong>Dimetil fumarat (DMF), MS hastalar\u0131 i\u00e7in kullan\u0131lan bir tedavi se\u00e7ene\u011fidir. Ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin n\u00f6rolojik h\u00fccrelere zarar verme riskini azaltarak etki g\u00f6sterir. DMF, RRMS semptomlar\u0131n\u0131 y\u00f6netmek i\u00e7in kullan\u0131lan bir ila\u00e7t\u0131r.<\/p>\n\n\n\n
Natalizumab, daha \u00f6nce de bahsedildi\u011fi gibi MS hastalar\u0131na yard\u0131mc\u0131 olmas\u0131 i\u00e7in kullan\u0131lan bir ila\u00e7t\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi h\u00fccrelerinin beyne giri\u015fini engelleyerek sinir h\u00fccrelerini koruyabilir. RRMS semptomlar\u0131n\u0131 y\u00f6netmek ve hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatmak i\u00e7in kullan\u0131l\u0131r.
Bu ila\u00e7lar, MS hastalar\u0131n\u0131n semptomlar\u0131n\u0131 y\u00f6netmek ve hastal\u0131\u011f\u0131 kontrol alt\u0131nda tutmak i\u00e7in yayg\u0131n olarak kullan\u0131lan ila\u00e7lard\u0131r. Ancak her bireyin tedaviye yan\u0131t\u0131 farkl\u0131 olabilece\u011finden, en uygun tedavi se\u00e7ene\u011fini belirlemek i\u00e7in doktorla birlikte de\u011ferlendirme yap\u0131lmal\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"